Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
+44 1300 500008
ISSN: 2376-0419
+44 1300 500008
Hyun Ok Yang
Korea Institute of Science & Technology, Republic of Korea
Scientific Tracks Abstracts: J Pharma Care Health Sys
Aim of the Study: Previous studies in our laboratory revealed the neuroprotective effect of modified Yeoldahanso-tang (MYH) in models of Parkinson�s disease (PD). In this study, we investigated another traditional Korean herbal formula, modified Chungsimyeoldatang (termed DG), as a potential treatment for PD. Chungsimyeolda-tang has been used in Korea to treat cerebrovascular diseases, such as stroke. Here, we verify the neuroprotective and autophagy-inducing effects of DG to evaluate any potential anti-parkinsonian properties. Materials & Methods: 1-Methyl-4-phenylpyridinium (MPP+) and rotenone were used to induce cytotoxicity in nerve growth factor (NGF)-differentiated rat pheochromocytoma (PC12) cells. Cell viability was measured using an MTT assay. Induction of autophagy by DG in NGF-differentiated PC12 cells was measured using an immunoblotting assay with an LC3 antibody. The proteasomal inhibitor lactacystin was used to induce ubiquitin-proteasome system (UPS) dysfunction in NGF-differentiated PC12 cells. DGmediated clearance of aggregated proteins was measured using an immunoblotting assay with an ubiquitin antibody. Results & Conclusions: Our findings indicate that DG robustly protects NGF-differentiated PC12 cells against the neurotoxic effects of MPP+ and rotenone in an in vitro model. Furthermore, DG protects NGF-differentiated PC12 cells against lactacystin-induced cell death. This effect is partially mediated by an increase autophagy associated with the enhanced degradation of aggregated proteins. This study suggests that DG is an attractive candidate drug for inducing autophagy and, therefore, may represent a promising strategy to prevent diseases associated with misfolded/aggregated proteins in various neurodegenerative disorders, including Parkinson�s disease.
Hyun Ok Yang has completed her PhD on pharmacognosy at Seoul National University in 1993. After Post-doctoral study at University of Iowa, USA, she is now a principal research scientist at Natural Products Research Center in Korea Institute of Science & Technology, Republic of Korea.
Email: hoyang@kist.re.kr